Vaxart

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in 2004 and is headquartered in South San Francisco, CA.

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in 2004 and is headquartered in South San Francisco, CA.

Vaxart (VXRT) has been working on developing a coronavirus vaccine. Increased clinical activity is expected to have increased expenses.

Coronavirus Vaccine Efforts Key to Vaxart (VXRT) Q2 Earnings

San Francisco, California--(Newsfile Corp. - August 3, 2020) -  Hagens Berman urges Vaxart, Inc.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Vaxart (VXRT) Investors Who Suffered $50K+ Losses and Persons Who May Assist Firm's Investigation of Possible Securities Fraud to Contact Its Attorneys Now

LOS ANGELES--(BUSINESS WIRE)---- $VXRT #VXRT--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Vaxart, Inc.

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Vaxart, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

Heat Biologics

Heat Biologics and Vaxart could have a lot more room to run.

2 Risky Coronavirus Vaccine Stocks That Could Make You Filthy Rich

Arcturus Therapeutics

iBio

The potential rewards are high. But so are the risks.

3 Small-Cap Coronavirus Stocks That Could Skyrocket

San Francisco, California--(Newsfile Corp. - July 31, 2020) - Hagens Berman urges Vaxart, Inc.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Vaxart (VXRT) Investors with Significant Losses and Persons Who May Assist Firm's Investigation of Possible Securities Fraud to Contact Its Attorneys Now

LOS ANGELES--(BUSINESS WIRE)---- $VXRT #VXRT--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Vaxart, Inc.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Vaxart, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces investigation of potential securities claims on behalf of shareholders of Vaxart, Inc. (NASDAQ: VXRT) resulting from allegations that Vaxart may have issued materially misleading business information to the investing public.

ROSEN, A TOP RANKED LAW FIRM, Announces Investigation of Securities Claims Against Vaxart, Inc. – VXRT

ATLANTA--(BUSINESS WIRE)--Holzer & Holzer, LLC is investigating whether Vaxart, Inc. (“Vaxart” or the “Company”) (NASDAQ: VXRT) complied with federal securities laws.

SHAREHOLDER ALERT: Investigation of Vaxart Announced by Holzer & Holzer, LLC

New York, New York--(Newsfile Corp. - July 28, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Vaxart, Inc.

Vaxart Investor Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Vaxart, Inc. To Contact The Firm

This company has more than its COVID-19 programs going for it.

This Coronavirus Stock Just Got More Attractive: Should You Buy?

AstraZeneca

Nasdaq Pharm Shs Nasdaq Pharmaceuticals

ETFMG Treatments Testing & Advancements ETF

Renaissance IPO ETF

Moderna

Novavax

Pfizer

VanEck Vectors Pharmaceutical ETF

Invesco DWA Healthcare Momentum ETF

There are at least a hundred candidates in the COVID-19 vaccine race globally. However, few companies like Moderna, Pfizer and AstraZeneca are showing considerable hope.

COVID-19 Vaccine Push Brings Hope: Stock & ETF Beneficiaries

Inovio Pharmaceuticals

Two biotechs with promising COVID-19 vaccine candidates. But one is the clear winner right now.

Better Coronavirus Stock: Inovio vs. Vaxart

PHILADELPHIA, July 27, 2020 /PRNewswire/ -- Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Vaxart, Inc.

Vaxart Investors With Losses Greater Than $50,000 Encouraged To Contact Kehoe Law Firm, P.C.

NEW YORK--(BUSINESS WIRE)-- #Investigation--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Vaxart, Inc.

VAXART ALERT: Bragar Eagel & Squire, P.C. is Investigating Vaxart, Inc.

LOS ANGELES--(BUSINESS WIRE)---- $VXRT #fraud--Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Vaxart, Inc. (VXRT) on Behalf of Investors

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Vaxart, Inc. (VXRT) on Behalf of Investors

BERWYN, Pa., July 27, 2020 /PRNewswire/ -- RM LAW, P.C.

RM LAW Announces Investigation of Vaxart, Inc.

NEW YORK, July 27, 2020 /PRNewswire/ -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Vaxart, Inc. ("Vaxart" or the "Company") (NASDAQ: VXRT).

Investor Alert: Kaplan Fox Investigates Potential Securities Fraud At Vaxart, Inc.

LOS ANGELES--(BUSINESS WIRE)---- $VXRT #classaction--The Law Offices of Frank R. Cruz announces an investigation on behalf of Vaxart, Inc.

The Law Offices of Frank R. Cruz Announces Investigation of Vaxart, Inc.

BENSALEM, Pa.--(BUSINESS WIRE)---- $VXRT #fraud--INVESTOR ALERT: Law Offices of Howard G.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Vaxart, Inc.

SAN DIEGO, July 27, 2020 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP, is investigating potential claims against Vaxart, Inc. (NASDAQ: VXRT) for violations of federal securities laws.

VXRT Alert: Johnson Fistel Launches Investigation into Vaxart, Inc. - Investors Suffering Losses Encouraged to Contact Firm

NEW YORK, July 27, 2020 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, is investigating potential claims on behalf of shareholders of Vaxart, Inc. ("Vaxart" or the "Company") (NASDAQ: VXRT) arising from allegations that Vaxart's Board of Directors may.

VXRT SHAREHOLDER INVESTIGATION: Bernstein Liebhard Announces an Investigation into Vaxart, Inc., and Encourages Investors to Contact the Firm

Co-Diagnostics

These stocks have delivered gains of 2,300% and more. But could they go even higher?

News for Vaxart Stock (VXRT)